Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266734 | 0.90 | SRC (0.49) | LTA4HBACE1AXLBRD4JAK1 | |
| SCHEMBL267158 | 0.90 | SLC2A1 (0.51) | LTA4HBACE1SLC2A1AXLBRD4 | |
| SCHEMBL265641 | 0.86 | AXL (0.47) | BACE1SLC2A1AXLSRCRET | |
| SCHEMBL264781 | 0.84 | ADORA2A (0.46) | LTA4HSLC2A1AXLBRD4JAK1 | |
| SCHEMBL265183 | 0.83 | BRD4 (0.47) | LTA4HSLC2A1AXLBRD4JAK1 | |
| SCHEMBL265815 | 0.83 | AXL (0.51) | BACE1AXLSRCRETTYK2 | |
| SCHEMBL265050 | 0.81 | LTA4H (0.48) | LTA4HBACE1AXLBRD4JAK2 | |
| SCHEMBL265711 | 0.78 | LTA4H (0.52) | LTA4HAXLBRD4JAK1JAK2 | |
| SCHEMBL270660 | 0.77 | JAK3 (0.72) | LTA4HBACE1SLC2A1AXLBRD4 | |
| SCHEMBL266079 | 0.77 | BRD4 (0.57) | SLC2A1AXLBRD4JAK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | LTA4H 626/4885BACE1 4487/4885SLC2A1 4666/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | LTA4H 3846/4885BACE1 4739/4885SLC2A1 4727/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | LTA4H 3846/4885BACE1 4739/4885SLC2A1 4727/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | LTA4H 3846/4885BACE1 4739/4885SLC2A1 4727/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | LTA4H 3846/4885BACE1 4739/4885SLC2A1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.